AugmentSM Treatment

Through extraordinary innovation, OvaScience seeks to transform the world’s understanding of a woman’s biology and empower women worldwide.


The AUGMENT treatment is specifically designed to improve a patient’s egg health. Improved egg health may offer the potential for enhanced IVF.1 It is a new approach to enhancing IVF that is designed for patients who want to use their eggs during IVF, but have compromised egg health due to poor egg quality, age or other reasons.

Prior to the discovery of egg precursor (EggPCSM) cells, IVF specialists used mitochondria from other sources (donor eggs) to supplement the energy needs in the egg. These doctors saw an improvement in embryo development and IVF success rates.2 With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells, immature egg cells found in the protective ovarian lining, are added to the patient’s mature eggs to supplement the existing mitochondria.

The AUGMENT treatment is OvaScience’s first available fertility treatment. It is available in certain IVF clinics in select international regions.

This website contains information about the AUGMENTSM treatment, which is available in certain IVF clinics in select international countries. The AUGMENT treatment is not available in the United States. Each country has specific laws, regulations and medical practices governing the communication of information about medical treatments. This is not a solicitation or promotion for any treatment which is not authorized by the laws and regulations of the country where the reader resides.

1Studies published in peer-reviewed medical journals, including Molecular Human Reproduction (1998), Human Cell (2004), Electronic Journal of Biology (2005), Reproduction Research (2006), Human Reproduction (2001) and Reproductive Biomedicine (2011), involved a number of species, including humans, in which third-party scientists demonstrated that the addition of mitochondria to eggs increased cellular energy levels, egg quality and the likelihood of fertilization and healthy live births.

2Tilly JL, Sinclair DA. Germline Energetics, Aging, and Female Infertility. Cell Metab. 2013; 17(6): 838-50. doi:10.1016/j.cmet.2013.05.007 and Chappel S. The Role of Mitochondria from Mature Oocyte to Viable Blastocyst. Obstetrics and Gynecology International. 2013: 10. doi:10.1155/2013/183024